Seoul, Korea and Heidelberg, Germany, July, 17, 2024 – SK Biopharmaceuticals, a global biotech company, announced today that it has entered into a license agreement with Full-Life Technologies (“Full-Life”), a fully integrated global radiotherapeutics company, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life’s “FL-091” radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers.
This licensing deal worth $571.5 million, which includes an upfront payment, and development and commercial milestones, separate from royalties, is in line with SK Biopharmaceuticals’ vision to become a global “Big Biotech” with R&D and commercialization capabilities extending beyond the central nervous system treatment area into oncology via emerging modality platforms such as radiopharmaceutical therapy (RPT) and targeted protein degradation (TPD).

Under the terms of the agreement, SK Biopharmaceuticals will in-license the NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091 – as well as its back-up compounds – aimed at developing and commercializing it as an innovative anti-cancer drug.

FL-091 is a small-molecule radioligand vector designed to deliver targeted radiation therapy to cancer cells by binding specifically to NTSR1, a receptor protein, which is selectively overexpressed in various types of solid tumors, including colorectal cancer, prostate cancer, and pancreatic cancer.

SK Biopharmaceuticals also has a right of first negotiation to license other pre-selected RDC programs of Full-Life.

The licensing serves as a pivotal catalyst for SK Biopharmaceuticals’ inorganic momentum and strategic advancement to be a leading global player in the medium-term.

Lanny Sun, Chief Executive Officer of Full-Life, said, “This agreement with SK Biopharmaceuticals highlights the potential of FL-091 in advancing cancer treatment and demonstrates SK Biopharmaceuticals' unwavering commitment to building an oncology business around medical innovation. We look forward to future collaborations with SK Biopharmaceuticals, and to leveraging its expertise and resources to advance radiopharmaceutical therapy. The agreement is aligned with our strategic vision of fostering global partnerships and making a meaningful impact on patients worldwide.”

Donghoon Lee, Chief Executive Officer and President of SK Biopharmaceuticals, said, “The licensing agreement with Full-Life not only brings the two companies closer together for future collaborations in the fastest rising biotech sector, but also most importantly, pushes SK Biopharmaceuticals forward to become a ‘Big Biotech.’ Since the introduction of the company’s strategy roadmap to venture into radiopharmaceuticals last year, we have been on track toward our envisioned goal. We expect to further unveil and implement business plans for RPT this year, and actively pursue clinical development and commercialization in the near future to provide treatment options and create new value worldwide.”

About FL-091
FL-091 is a novel small-molecule radioligand vector targeting NTSR1 positive solid tumors. Overexpression of NTSR1 has been associated with disease progression of multiple types of cancers, including colorectal, breast, pancreatic, and head and neck cancers. FL-091 radioligands have demonstrated favorable biodistribution profiles and enhanced binding affinity to NTSR1, as well as encouraging anti-tumor activities in preclinical studies. The development of the alpha-emitter therapy candidate 225Ac-FL-091 targeting NTSR1-positive tumors is currently in progress.

About SK Biopharmaceuticals 
SK Biopharmaceuticals focuses on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts. 
SK Biopharmaceuticals is the first and only Korean company to independently develop and commercialize an antiseizure medication, cenobamate (brand name: XCOPRI®) in the U.S. More than 100,000 patients have been treated globally with cenobamate, developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, Inc., since its launch in the U.S. in 2020. Cenobamate has successfully entered five major regions: North America, Europe, Asia, Central and South America, and the Middle East and North Africa.

The company also has a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals’ website at www.SKBP.com/eng, and SK Life Science’s website at www.SKLifeScienceInc.com.

About Full-Life Technologies
Full-Life Technologies ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.
Media Contacts:
H. Park
SK Biopharmaceuticals
Email: skbp_comm@sk.com

Full-Life 
Email: pr@t-full.com
Source: SK Biopharmaceuticals